Chang Gung Memorial Hospital

Running trials

• Enrolling by invitation

  Physical Activity Interventions for Sleep Improvement and Sedative-Hypnotic Reduction in Middle-Aged and Older Adults: Investigating the Role of Sarcopenia

  NCT07896603· Chang Gung Memorial Hospital· Source

• Not yet recruiting

  Fractional Exhaled Nitric Oxide and Exacerbations of COPD

  NCT07396311· Chang Gung Memorial Hospital· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

  NCT06468033· Phase 3· PharmaEssentia· Source

• Active, not recruiting

  Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals

  NCT06507059· Phase 3· Chang Gung Memorial Hospital· Source

• Recruiting

  The Registry of Genetic Alterations of Taiwan Ovarian Cancer

  NCT06127446· National Health Research Institutes, Taiwan· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  NCT05797610· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05559359· Phase 3· Eli Lilly and Company· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Johnson & Johnson Enterprise Innovation Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

  NCT05144854· Phase 3· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

  NCT05048901· Phase 1/2· National Health Research Institutes, Taiwan· Source

• Active, not recruiting

  A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

  NCT05049798· Janssen Pharmaceutica N.V., Belgium· Source

• Recruiting

  The Research Plan of Taiwan Precision Medicine

  NCT04849481· National Health Research Institutes, Taiwan· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Active Psoriatic Arthritis

  NCT04882098· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

  NCT04576156· Phase 3· Geron Corporation· Source

• Active, not recruiting

  A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

  NCT04538664· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04487080· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

  NCT04404283· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

  NCT03888105· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial

  NCT06193733· Phase 2· Chang Gung Memorial Hospital· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Neuroendocrine tumours2 recruiting
• COPD1 recruiting
• Head and neck cancer1 recruiting
• Insomnia1 recruiting
• Ovarian cancer1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Effectiveness Evaluation of a Self-management Program for Prostate Cancer Survivors

  NCT05335967· National Taipei University of Nursing and Health Sciences· Source

• Completed

  Real-world Clinical Benefit Evaluation in Breast Cancer Patients With Pharmaceutical Interventions for Cancer-related Fatigue

  NCT05428527· National Defense Medical Center, Taiwan· Source

• Completed

  CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

  NCT04860830· Phase 3· Boehringer Ingelheim· Source

• Completed

  Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients

  NCT04988750· NaviFUS Corporation· Source

• Completed

  A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

  NCT04533529· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

  NCT04082364· Phase 2/3· MacroGenics· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Alfasigma S.p.A.· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer83 works · 1 trial
• Obstructive sleep apnoea25 works · 0 trials
• Psoriasis18 works · 2 trials
• Lupus (SLE)18 works · 0 trials
• Head and neck cancer17 works · 1 trial
• Macular degeneration16 works · 0 trials
• Diabetic eye disease15 works · 0 trials
• Hepatitis C13 works · 0 trials
• Cerebral palsy9 works · 0 trials
• Cytomegalovirus infection8 works · 0 trials
• Hepatitis B8 works · 0 trials
• Myeloproliferative neoplasms7 works · 2 trials
• Chronic rhinosinusitis with nasal polyps7 works · 0 trials
• Liver cirrhosis6 works · 0 trials
• Alopecia areata5 works · 0 trials
• Vitiligo5 works · 0 trials
• Retinitis pigmentosa4 works · 0 trials
• Narcolepsy3 works · 0 trials